Candel Therapeutics (NASDAQ:CADL) Stock Gets Downgrade from Zacks Research

Posted by Stanley Muller on Oct 16th, 2026

Candel Therapeutics (NASDAQ:CADL – Get Free Report) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Wednesday, Zacks reports.

CADL has been the topic of a number of other research reports. Stifel Nicolaus began coverage on Candel Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $22.00 target price on the stock. Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Bank of America raised shares of Candel Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the company from $12.00 to $18.00 in a report on Monday, September 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Candel Therapeutics in a research report on Friday, October 2nd. Nine analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $20.14.

Get Our Latest Report on Candel Therapeutics

Candel Therapeutics Stock Performance

Candel Therapeutics stock opened at $8.91 on Wednesday. Candel Therapeutics has a fifty-two week low of $4.35 and a fifty-two week high of $14.00. The company has a debt-to-equity ratio of 0.38, a current ratio of 16.09 and a quick ratio of 16.09. The company has a market cap of $681.78 million, a P/E ratio of -6.32 and a beta of -0.32. The firm’s 50 day simple moving average is $11.43 and its 200-day simple moving average is $9.32.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.28). As a group, equities research analysts predict that Candel Therapeutics will post -1.29 EPS for the current year.

Insider Buying and Selling

In other news, CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction on Monday, August 17th. The stock was sold at an average price of $12.00, for a total value of $84,000.00. Following the completion of the sale, the chief technology officer directly owned 76,865 shares of the company’s stock, valued at approximately $922,380. This trade represents a 8.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 14.30% of the company’s stock.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors have recently made changes to their positions in CADL. WINTON GROUP Ltd acquired a new position in Candel Therapeutics during the second quarter valued at approximately $384,000. Squarepoint Ops LLC acquired a new stake in shares of Candel Therapeutics in the second quarter valued at approximately $775,000. AXQ Capital LP lifted its position in shares of Candel Therapeutics by 50.8% in the second quarter. AXQ Capital LP now owns 31,460 shares of the company’s stock worth $324,000 after purchasing an additional 10,596 shares in the last quarter. Cookson Peirce & Co. Inc. acquired a new position in shares of Candel Therapeutics during the 2nd quarter worth about $618,000. Finally, Wellington Management Group LLP acquired a new position in Candel Therapeutics during the second quarter valued at approximately $2,119,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Candel Therapeutics Company Profile

(Get Free Report)

Candel Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing biological immunotherapies designed to stimulate and strengthen the body’s immune response against cancer. The company’s approach uses engineered viruses intended to selectively target tumors and activate broader antitumor immunity.

Candel’s pipeline includes CAN-3110, an investigational oncolytic immunotherapy being developed for high-grade glioma, including recurrent glioblastoma. The company is also developing CAN-2409, a non-replicating adenovirus-based therapy designed to work with a prodrug to trigger localized cancer-cell destruction and immune activation.